Maze Therapeutics (NASDAQ:MAZE) Announces Quarterly Earnings Results

Maze Therapeutics (NASDAQ:MAZE) posted its quarterly earnings data on Tuesday. The company reported ($0.76) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.76), Zacks reports.

Maze Therapeutics Price Performance

Shares of Maze Therapeutics stock traded up $0.03 during trading on Tuesday, hitting $27.31. The stock had a trading volume of 379,878 shares, compared to its average volume of 669,188. The firm has a market cap of $1.51 billion, a price-to-earnings ratio of -10.79 and a beta of 2.22. Maze Therapeutics has a 12 month low of $12.81 and a 12 month high of $53.65. The business’s 50-day moving average is $27.57 and its 200 day moving average is $33.44. The company has a current ratio of 17.88, a quick ratio of 17.88 and a debt-to-equity ratio of 0.11.

Insider Activity

In related news, CMO Harold Bernstein sold 14,609 shares of the company’s stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $29.90, for a total value of $436,809.10. Following the completion of the transaction, the chief marketing officer directly owned 14,609 shares in the company, valued at approximately $436,809.10. The trade was a 50.00% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Jason V. Coloma sold 34,501 shares of the company’s stock in a transaction dated Wednesday, July 1st. The stock was sold at an average price of $29.98, for a total value of $1,034,339.98. Following the completion of the transaction, the chief executive officer owned 23,337 shares of the company’s stock, valued at $699,643.26. The trade was a 59.65% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 141,470 shares of company stock worth $3,902,714. 5.30% of the stock is currently owned by insiders.

Institutional Trading of Maze Therapeutics

Several hedge funds have recently added to or reduced their stakes in MAZE. Goldman Sachs Group Inc. purchased a new position in shares of Maze Therapeutics in the first quarter worth about $145,000. Legal & General Group Plc grew its holdings in shares of Maze Therapeutics by 23.0% in the third quarter. Legal & General Group Plc now owns 5,219 shares of the company’s stock worth $135,000 after purchasing an additional 977 shares during the last quarter. Engineers Gate Manager LP purchased a new stake in Maze Therapeutics during the 2nd quarter valued at $125,000. Rhumbline Advisers bought a new position in shares of Maze Therapeutics during the first quarter valued at about $80,000. Finally, Bank of America Corp DE raised its position in Maze Therapeutics by 33.6% during the 2nd quarter. Bank of America Corp DE now owns 5,782 shares of the company’s stock valued at $71,000 after purchasing an additional 1,455 shares during the last quarter.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on the company. Weiss Ratings restated a “sell (d-)” rating on shares of Maze Therapeutics in a research note on Wednesday, June 24th. Truist Financial lowered their target price on Maze Therapeutics from $68.00 to $64.00 and set a “buy” rating on the stock in a research note on Tuesday, April 14th. Finally, Wall Street Zen upgraded shares of Maze Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, May 16th. Two research analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, Maze Therapeutics has a consensus rating of “Buy” and an average target price of $66.00.

About Maze Therapeutics

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.